LFA
VRTX icon

LGT Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

LGT Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.79K Hold
4
– – 0.01% 232
2025
Q4 		$1.81K Hold
4
– – 0.01% 237
2025
Q3 		$1.57K Hold
4
– – ﹤0.01% 345
2025
Q2 		$1.78K Buy
+4
New +$1.84K ﹤0.01% 364
2024
Q3 		– Sell
-38
Closed -$17.8K – 793
2024
Q2 		$17.8K Buy
+38
New +$16.5K 0.04% 328
2024
Q1 		– Sell
-16
Closed -$6.51K – 864
2023
Q4 		$6.51K Hold
16
– – 0.01% 568
2023
Q3 		$5.56K Buy
+16
New +$5.6K 0.01% 590

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

LGT Financial Advisors's VRTX Position: Q1 2026 in Review

LGT Financial Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 4 shares worth $1.79K. The position accounts for 0.01% of the portfolio, ranked #232.

LGT Financial Advisors first reported a position in VRTX in Q3 2023 and has held it in 7 quarters since. The position peaked at $17.8K in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • LGT Financial Advisors held 4 shares of Vertex Pharmaceuticals worth $1.79K as of Q1 2026.
  • LGT Financial Advisors left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up 0.01% of LGT Financial Advisors's portfolio in Q1 2026, its #232 holding.
  • LGT Financial Advisors first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 7 quarters since.
  • LGT Financial Advisors's Vertex Pharmaceuticals position peaked at $17.8K in Q2 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on LGT Financial Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.